Claims for Patent: 11,045,460

Summary for Patent: 11,045,460

Title:	Use of Hsp70 as a regulator of enzymatic activity
Abstract:	The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.
Inventor(s):	Thomas Kirkegaard Jensen, Marja H. Jaattela
Assignee:	Zevra Denmark AS
Application Number:	US16/698,092
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,045,460
Patent Claims:	1. A method for treating Niemann-Pick disease Type C (NPC) in a human comprising orally administering arimoclomol, or a pharmaceutically acceptable salt thereof, to the human. 2. The method of claim 1, wherein the human is orally administered a daily dosage of arimoclomol, or a pharmaceutically acceptable salt thereof, of from about 1 ug to about 100 mg per kilogram of body weight. 3. The method of claim 2, further comprising administering Miglustat to the human. 4. The method of claim 2, further comprising administering enzyme replacement therapy to the human. 5. The method of claim 4, wherein the enzyme replacement therapy is imiglucerase, agalsidase beta, or agalsidase alpha.